TO BETTER UNDERSTAND TREATMENT RESISTANCE AND CANCER PROGRESSION, OUR LAB STUDIES HOW CELL DEATH PATHWAYS ARE REGULATED UNDER STRESS.

Cells constantly face stimuli that disrupt homeostasis and have evolved mechanisms to survive such challenges. We investigate these responses using 2D/3D models and advanced microscopy.

A core focus is the multifunctional role of BCL2 family proteins. Beyond intrinsic apoptosis, these proteins regulate mitochondrial metabolism and other processes. We aim to define their non-canonical roles in cancer cells and how they support stress adaptation and therapy resistance.

We also study entosis, a form of cell death where one cell actively internalizes another. This process can benefit the host cell while eliminating the internalized one. We seek to determine its role in cancer progression, identify stressors that induce it, and discover compounds to modulate it.
Additionally, we investigate resistance driven by therapy-induced senescence in breast cancer. CDK4/6 inhibitors induce a senescent state, but senescent cells may persist and promote relapse through secretory and metabolic changes. Our goal is to dissect the molecular features of this state and identify vulnerabilities that can be targeted to improve therapeutic outcomes.

PRESENTATION

GET TO KNOW US BETTER

  • Own scientific image of the laboratory
  • Own scientific image of the laboratory

RESEARCH STAFF

THE PEOPLE WHO MAKE IT ALL POSSIBLE

Federico Lucantoni 
flucantoni@cipf.es

Carolina Gandía Ventura
cgandia@cipf.es

PUBLICATIONS

OUR SCIENTIFIC CONTRIBUTIONS

Implication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less.

Lucantoni F, Benedicto AM, Gruevska A, Moragrega ÁB, Fuster-Martínez I, Esplugues JV, Blas-García A and Apostolova N

Cell Death & Disease 2022 Apr,  DOI:  10.1038/s41419-022-04789-7,  Vol. 13,  pag. 385-385

READ PUBLICATION

BCL(X)L and BCL2 increase mitochondrial dynamics in breast cancer cell: Evidence from functional and genetic studies.

Lucantoni F, Salvucci M, Dussmann H and Prehn JHM

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2021 Sep,  DOI:  10.1016/j.bbamcr.2021.119095,  Vol. 1868,  pag. 119095-119095

READ PUBLICATION

BCL(X)L and BCL2 increase the metabolic fitness of breast cancer cells: a single-cell imaging study.

Lucantoni F, Salvucci M, Düssmann H, Lindner AU, Lambrechts D and Prehn JHM

CELL DEATH AND DIFFERENTIATION 2021 May,  DOI:  10.1038/s41418-020-00683-x,  Vol. 28,  pag. 1512-1531

READ PUBLICATION

Metabolic Targeting of Breast Cancer Cells With the 2-Deoxy-D-Glucose and the Mitochondrial Bioenergetics Inhibitor MDIVI-1.

Lucantoni F, Dussmann H and Prehn JHM

Frontiers in Cell and Developmental Biology 2018 Sep,  DOI:  10.3389/fcell.2018.00113,  Vol. 6,  pag. 113-113

READ PUBLICATION

Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells.

Lucantoni F, Lindner AU, O'Donovan N, Düssmann H and Prehn JHM

Cell Death & Disease 2018 Jan,  DOI:  10.1038/s41419-017-0039-y,  Vol. 9,  pag. 42-42

READ PUBLICATION

FUNDING

THANK YOU FOR SUPPORTING US